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ABSTRACT
Limited sensitivity of existing assays has preven-
ted investigation of whether Adriamycin–DNA add-
ucts are involved in the anti-tumour potential of
Adriamycin. Previous detection has achieved a sen-
sitivity of a few Adriamycin–DNA adducts/10
4bp
DNA, but has required the use of supra-clinical
drug concentrations. This work sought to measure
Adriamycin–DNA adducts at sub-micromolar doses
using accelerator mass spectrometry (AMS), a tech-
nique with origins in geochemistry for radiocarbon
dating. We have used conditions previously
validated (by less sensitive decay counting) to
extract [
14C]Adriamycin–DNA adducts from cells
and adapted the methodology to AMS detection.
Here we show the first direct evidence of
Adriamycin–DNA adducts at clinically-relevant
Adriamycin concentrations. [
14C]Adriamycin treat-
ment (25nM) resulted in 4.4±1.0 adducts/10
7bp
(~1300 adducts/cell) in MCF-7 breast cancer
cells, representing the best sensitivity and preci-
sion reported to date for the covalent binding
of Adriamycin to DNA. The exceedingly sensitive
nature of AMS has enabled over three orders
of magnitude increased sensitivity of Adriamycin–
DNA adduct detection and revealed adduct for-
mation within an hour of drug treatment. This
method has been shown to be highly repro-
ducible for the measurement of Adriamycin–DNA
adducts in tumour cells in culture and can now
be applied to the detection of these adducts in
human tissues.
INTRODUCTION
The anthracyclines are a group of chemotherapeutics that
include Adriamycin (doxorubicin), daunorubicin, idarubi-
cin and epirubicin, and which have been widely used in the
clinic since the 1960s (1). Adriamycin (Figure 1) is active
against a broad range of tumours and is now commonly
used in the treatment of breast cancer, Hodgkin’s lym-
phoma, lung cancer, multiple myeloma and re-occurring
ovarian cancer (2). Adriamycin remains the anti-cancer
agent with the widest spectrum of anti-tumour activity;
however, resistance and side eﬀects are major limitations
to the success of Adriamycin therapy (3).
Although the exact mechanism by which Adriamycin
exerts its anti-tumour activity is uncertain, the dominant
mechanism of action appears to involve impairment of
topoisomerase IIa activity (4,5), consistent with observed
DNA intercalation and nuclear localization of
Adriamycin (6–8). Many potential alternative mechanisms
of action have been cited and comprehensively reviewed
(3,4). It is likely that Adriamycin acts by many diﬀerent
mechanisms to kill tumour cells, and this would be con-
sistent with its broad spectrum activity.
One of these possible mechanisms, Adriamycin–DNA
adduct formation, was ﬁrst reported in 1979 by Sinha
and Chignell (9), but the adducts were diﬃcult to isolate
and characterize. A complicating factor in the chemistry
of the DNA adduct formation is the participation of for-
maldehyde in vivo, which activates the compound to a
more reactive electrophile capable of forming covalent
adducts with DNA (10). The requirements for formation
of formaldehyde-mediated Adriamycin–DNA adducts
have now been well characterized and reviewed recently
by Cutts and co-workers (10,11) and their structure char-
acterised (12–14). It is uncertain whether the adducts ﬁrst
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as the formaldehyde-mediated adducts. Early ﬁndings by
Konopa (15) and many other researchers since (16–21)
supported the hypothesis that Adriamycin could form
adducts that functioned essentially to cross-link DNA in
cells, although methods to detect the adducts were limited
in their sensitivity and required the use of supra-clinical
drug concentrations (typically  10mM Adriamycin)
(Table 1). In comparison, plasma concentrations of
Adriamycin typically achieved clinically for extended
periods of time are <250nM (4). Initially, isolation of
Adriamycin–DNA adducts was also hindered by their
intrinsic instability to both heat and alkali. Now that
the stability of the adduct has been extensively character-
ized, conditions have been established to facilitate their
isolation (22–24).
Detection of [
14C]Adriamycin–DNA adducts by liquid
scintillation counting (LSC) is now a straightforward pro-
cedure with few manipulations, hence minimal adduct
losses. However LSC is relatively insensitive and is
unable to accurately measure small quantities of
14C,
necessitating high speciﬁc activity radiolabelled com-
pounds and artiﬁcially high levels of the radiolabelled
drug. Previous LSC studies have used 2–10mM
Adriamycin for the detection of Adriamycin–DNA
adducts in cells (17). The lowest Adriamycin–DNA
adduct frequency typically measured by LSC in cells
(with good reproducibility) is a few adducts per 10
4bp
DNA following treatment with 2mM Adriamycin (16),
which is highly toxic to cells at this concentration.
Detection of such low concentrations of radiocarbon by
decay counting may be of limited relevance because
Adriamycin concentrations that achieve growth inhibition
in vitro are typically in the range of 20–400nM (25).
Assays of cellular responses to Adriamycin–DNA
adduct formation have alluded to their cytotoxicity, but
only at drug concentrations where adducts could not be
directly detected (i.e. the adducts were demonstrated
at concentrations that were much higher than necessary
for growth inhibition) (16,25). More recently, substantial
enhancement of Adriamycin–DNA adduct formation by
the use of formaldehyde-releasing pro-drugs has enabled
measurement of the adducts using lower doses of
Adriamycin (11).
The need for supra-clinical Adriamycin concentrations
to facilitate quantiﬁcation of Adriamycin–DNA adducts
has called into question whether adduct formation is
a clinically-relevant mechanism of action of the drug (4).
Therefore, a more sensitive method of accelerator mass
spectrometry (AMS) has been utilized for this report to
determine whether signiﬁcant levels of adducts were
formed at clinically relevant Adriamycin concentrations.
There are currently over 100 AMS instruments in use
worldwide for radiocarbon measurements, with approxi-
mately 5–10 instruments dedicated to biomedical research
located in academia and industry. AMS is a well-
established technology for radiocarbon dating and is
now in development for tracing
14C-labelled compounds
in biological systems, aﬀording sub-attomole
14C per mg
of total carbon sensitivity with a few percent precision
(26,27) and a 100- to 1000-fold improvement over
3H
decay counting techniques (28). For radiocarbon analysis,
the sample is typically converted to graphite via a two-step
chemical process. The graphite produces high ion currents
in the accelerator and allows for sensitive and precise mea-
surements without the need for internal standards. The
resulting data is in the form of a radiocarbon to total
carbon ratio that can be conveniently used to calculate
the concentration of
14C-labelled compound in the
sample. Pharmacokinetic studies have exploited AMS,
enabling the use of physiological doses of radiolabelled Figure 1. Structure of Adriamycin.
Table 1. Quantitative techniques used to detect Adriamycin–DNA adducts
Methodology Minimum
Adriamycin dose
Adducts per
10
7bp DNA
Sample source Reference
Chromatography speciﬁc for covalently
bound Adriamycin using an intercalator
aﬃnity column
a
50mM  1220 Cultured cells 66
Gene-speciﬁc and cross-linking assays 7.5mM 100 Cultured cells 17,67,68
32P DNA post-labelling 0.27mmol/2.5g tumour 10 Intra-tumoural injection into rat
mammary carcinoma (in vivo)
b
19
[
14C]Adriamycin bound to cellular DNA detected 1mmol/200g rat 70 Rat liver (in vivo)6 9
by decay counting 1mM 1 Cultured cells 16,25,44,70
aWith HPLC detection.
bDetected 3h post-injection.
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molecules have been measured in samples at levels as
low as one radiolabelled molecule per cell (29–31). AMS
has been utilized in the detection of DNA adducts
(e.g. DNA alkylating agents such as benzene, atrazine
and heterocyclic amines) (30) and has been cited as the
gold standard for DNA adduct detection because of its
extreme sensitivity (32). More recently, AMS has been
used to study the pharmacokinetics and cellular metabo-
lism of several drugs and nucleosides that result in DNA
adducts (33–37).
Previous reports have used high drug concentrations
(2–50mM Adriamycin), or formaldehyde activation of
Adriamycin, to enhance Adriamycin–DNA adduct forma-
tion [e.g. a Tris/iron-containing system (38) and formalde-
hyde-releasing drugs (11,16)]. In the present study we
tested the sensitivity of detection of Adriamycin–DNA
adducts by AMS using sub-micromolar concentrations
of Adriamycin in cultured breast cancer cells. An aim of
this work was to evaluate the use of AMS as a highly
sensitive methodology for quantifying total cellular
Adriamycin–DNA adducts and to assess the sensitivity
and speciﬁcity of AMS detection of Adriamycin–DNA
adducts at clinically relevant Adriamycin concentrations.
MATERIALS AND METHODS
Materials and cell lines
[
14C]Adriamycin hydrochloride (55mCi/mmol, 95.9%
chemical purity) was obtained from GE Healthcare
(Piscataway, NJ, USA) and dissolved in sterile Milli-Q
H2O to a concentration of 1mM and stored at  208C.
Tris-saturated phenol and trypsin-EDTA were obtained
from Invitrogen, Carlsbad, CA, USA; chloroform from
BDH, Dorset, UK; QIAamp Blood Kit from QIAGEN,
Valencia, CA, USA; glycogen from Roche Molecular
Biochemicals, Nutley, NJ, USA; Ready-Safe Scintillation
ﬂuid from Beckman Coulter, Fullerton, CA, USA and
Whatman GF/A ﬁlters from Whatman, Kent, UK.
Calf thymus DNA (CT-DNA) was obtained from
Worthington Biochemical Corporation, Lakewood, NJ,
USA and prepared by dissolving 60mg overnight at 48C
in 20ml Tris–EDTA pH 8 buﬀer with agitation and soni-
cated for six 30s bursts, resulting in 100bp to 5kb DNA
fragments. Fragmented DNA was then ethanol precipi-
tated and fully dissolved in 0.1 Tris–EDTA buﬀer to a
concentration of 2.5mM base pair DNA and particulate
matter removed by 5mm ﬁltration.
Distilled water passed through a four-stage Milli-Q puri-
ﬁcation system was used to prepare all solutions. Unless
otherwise speciﬁed, analytical grade reagents were used.
Cell lines
MCF-7 breast adenocarcinoma cells (39) and the MCF-7/
Dx Adriamycin-resistant sub-line were obtained from
Dr Rosanna Supino (Laboratorio Oncologia, Milan,
Italy) and maintained in RPMI (Sigma, MO, USA) sup-
plemented with 10% fetal bovine serum (Thermo
Scientiﬁc, Melbourne, Australia). MCF-7/Dx cells were
generated by growth in escalating Adriamycin
concentrations that resulted in increased expression of
the multidrug resistance pump P-glycoprotein, and were
maintained under selective pressure of 300nM
Adriamycin as previously reported (25,40). Antibiotics
were not used in cell line maintenance and all cell lines
were routinely tested for mycoplasma by ﬂuorescence
microscopy. All cell culture was carried out at 378Ci na
humidiﬁed atmosphere with 5% CO2.
Drug treatment of cells
On day 1 of Adriamycin–DNA adduct detection experi-
ments, 7.5 10
5 cells in 2ml of growth medium were
seeded in 35mm wells and allowed to attach overnight.
On day 2 the media was refreshed with new growth
media that had been equilibrated to 378Ci n5 %C O 2 over-
night, followed by drug treatment as required. Samples
were harvested using trypsin–EDTA at speciﬁed times
and washed twice with PBS. Cell pellets were stored at
 808C until required for further processing.
Clonogenicsurvival
Cells were seeded as described above and treated with
Adriamycin for 4h. Cells were then harvested and replated
at densities to give between 150 and 250 colonies/dish
(5ml/60mm dish in four replicate plates). Dishes were
incubated for 10 days, then colonies stained with 0.25%
(w/v) crystal violet in 2% (w/v) formaldehyde and 80%
(v/v) methanol. Colonies consisting of  50 cells were
counted. For each treatment the plating eﬃciency was
calculated and the surviving fraction assessed relative to
the untreated control.
Purification of Adriamycin–DNA adducts
Following drug treatments, cell pellets were resuspended in
150ml PBS and cellular DNA extracted using a QIAamp
Blood Kit according to the manufacturer’s instructions,
with the following four modiﬁcations to the standard pro-
cedure to minimize loss of the heat-labile adducts:
(1) 2mg/ml RNase A digestion was included during the
lysis;
(2) cell lysis was conducted at 508C for 30min (to mini-
mize the loss of heat-labile adducts);
(3) column-wash buﬀer AW2 was used in place of buﬀer
AW1 and
(4) DNA was eluted into 200ml Milli-Q H2O.
These modiﬁcations were previously established to max-
imize DNA yield with minimal adduct losses (16). DNA
was then subjected to a cleanup procedure involving
extraction twice with phenol and once with chloroform,
and then ethanol precipitated (2 volumes ethanol, 0.1
volume of 3M sodium acetate, 20mg glycogen) DNA pel-
lets were thoroughly washed twice with 70% ethanol and
allowed to dry.
Detectionof Adriamycin–DNA adduct by LSC
DNA pellets were resuspended in 100ml of Tris–EDTA
buﬀer pH 8, and the DNA concentration and quality
were determined using a Nanodrop ND-1000
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Incorporation of [
14C]Adriamycin was determined by LSC
of a 90ml aliquot of each sample with 1ml of Ready-Safe
Scintillation ﬂuid using a Wallac 1410 Liquid Scintillation
Counter (LSC). The amount of Adriamycin present in each
scintillated sample was determined by a LSC standard
curve of [
14C]Adriamycin standards (40–200 pmol Adria-
mycin). DNA concentrations were determined spectropho-
tometrically using an extinction coeﬃcient of 13200/Mbp/
1cm at 260nm. The frequency of Adriamycin–DNA
adducts was then calculated per 10
7bp DNA.
AMSprocedure
The procedure for measurement of Adriamycin–DNA
adducts by AMS was adapted from a method for prepara-
tion of DNA from tissues for AMS measurement (41) with
further modiﬁcations to minimize sample contamination.
AMS samples are highly susceptible to
14C contamination
and hence rigorous procedures must be observed to mini-
mize the possibility of contamination and to ensure repro-
ducible results. Many experimental aspects for the
prevention of contamination during preparation of AMS
samples have been documented previously (41,42).
Once DNA samples were puriﬁed as described above,
samples were prepared for submission to the AMS facility
at Lawrence Livermore National Laboratories (LLNL).
Details for the preparation and submission of samples
are described below. This procedure is a newly developed
methodology for the detection of Adriamycin–DNA
adducts and the ﬁrst reported detection of Adriamycin–
DNA adducts with such high sensitivity.
DNA pellets were thoroughly dissolved in 200mlo f
1mM NaCl and 100ml of each sample was sub-sampled
to a separate tube to be used for DNA quantiﬁcation and
scintillation (designated LAB). The remainder (designated
AMS) was stored at  208C for sample submission to the
AMS facility at LLNL for
14C measurement.
DNA concentrations of LAB samples (2ml per sample)
were determined using a Nanodrop ND-1000 spectropho-
tometer and the majority (90ml) of these samples was sub-
jected to LSC as described above. This preliminary LSC
measurement of each sample was taken to establish that
14C was within background levels as a precaution against
contaminating the AMS instrument.
DNA concentrations of AMS samples were adjusted by
dilution to the required concentration with 1mM NaCl.
Samples were prepared to give between an estimated
0–100 Fraction Modern (F. Mod.) per sample, which is
the appropriate level of
14C for AMS detection. Although
higher levels of
14C may be acceptable, 100F. Mod. is the
preferred maximum limit (10-fold below the point at
which the detector response becomes non-linear with
14C
concentration). Samples for submission to LLNL were
prepared by drying a volume of each sample onto
Whatman GF/A ﬁlters. Samples were usually prepared
as equal volumes dispensed onto ﬁlters to yield approxi-
mately equal DNA quantities (although in some cases it
was necessary to alter the quantity of DNA in each sample
submitted for AMS measurement in order to ensure that
the samples would fall within the acceptable range of
detection of 0–100F. Mod. per sample). Filters were
dried overnight in a laminar ﬂow hood protected from
UV lights. At LLNL, AMS samples were prepared from
puriﬁed DNA after addition of carrier carbon in the
form of 1ml of tributyrin (equivalent to 0.62±0.02mg
of carbon) (ICN Chemical Co.). AMS samples were ana-
lysed as described below (Detection of Adriamycin–DNA
adducts by AMS section).
The remainder of each of the equalized AMS samples
was then measured for DNA content (Nanodrop ND-100)
to determine the precise DNA concentration of the diluted
sample that was submitted to LLNL for AMS measure-
ment. The precisely determined DNA quantities were used
for subsequent DNA adduct calculations.
Measurement of thetemporal stability of
Adriamycin–DNA adducts
The stability of [
14C]Adriamycin–DNA adducts was
assessed by subjecting DNA extracted from the drug-
exposed cells to increasing times of incubation in PBS at
378C. Samples were frozen until required and then sub-
jected to the clean-up procedure again prior to AMS mea-
surement of the remaining DNA-bound radiocarbon.
Detection ofAdriamycin–DNA adducts byAMS
The measurement of DNA samples by AMS was carried
out at the Biomedical AMS Research Resource at LLNL.
The AMS method described was adapted from previous
publications (41,42). DNA samples ranging from 0.5 to
2.5mg DNA were prepared for AMS measurement as
described above. For each sample the results were
reported as F. Mod. (a ratio of Ctotal:
14C in a sample as
a fraction of the standard Modern value, which is
9.79 10
 17mole
14C/mg of total carbon). The F. Mod.
was then calculated per mg of DNA and then corrected for
the vehicle control.
The frequencies of Adriamycin–DNA adducts were
determined using the following calculations. In order to
determine the quantity of Adriamycin bound to DNA,
F. Mod. was converted to an absolute quantity of
14C
per sample compared to the 0.62mg of carrier carbon
(Ccarrier). The quantity of DNA in each case added negli-
gible carbon to the sample. For one F. Mod. in a 0.62mg
sample of carbon, the number of moles of
14C [n(
14C)]
is deﬁned by:
nð14CÞ¼1 modern 14C  
9:79   10 17 14C
mg C
  0:62 mg Ccarrier ¼ 6:07   10 17 mol 14C
1
For one F. Mod., the number of moles of Adriamycin,
n(Adr), was then calculated from the speciﬁc activity of
[
14C]Adriamycin (55mCi/mmol; 0.8814 atoms
14C/mole-
cule of Adriamycin).
nðAdrÞ¼
Eq1
specific activity
¼
6:07   10 17 mol 14C
0:8814 14C
molecule of Adr

¼ 6:89   10 17 mol Adr
2
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quantity using MWbp of 653.72g/mol and Adriamycin–
DNA adducts per bp DNA were then calculated. One
F. Mod. of
14C per mg DNA can then be converted to
Adriamycin adducts per 10
7bp DNA as deﬁned by
Equation (3) below, where f=n(
14C) in F. Mod. and
D=n(DNA) in mg.
Adriamycin adducts per 107 bp DNA ¼
f
D
  0:450 3
RESULTS
The puriﬁcation of Adriamycin–DNA adducts was depen-
dant on the eﬃcient extraction of non-covalently bound
Adriamycin into phenol. This eﬃciency was conﬁrmed by
mixing [
14C]Adriamycin with CT-DNA which was then
subjected to stepwise phenol extractions followed by one
chloroform extraction and the remaining
14C measured by
LSC. The extraction eﬃciency of one phenol extraction
(followed by one chloroform extraction) was found to be
90%; however, only 4% further removal of Adriamycin
resulted from a second phenol extraction. No further
removal of Adriamycin was observed in the two subse-
quent phenol extractions. A single chloroform extraction
alone resulted in 13% removal of Adriamycin (without
any phenol extractions). For subsequent experiments ade-
quate removal of non-covalently bound Adriamycin was
achieved with two phenol extractions, followed by one
chloroform extraction.
Adriamycin–DNA adducts have previously been
detected in cells using radiolabelled Adriamycin and
decay counting (16,25,44), hence the more sensitive tech-
nique of AMS was expected to permit the detection of
lower levels of adducts using a similar procedure for
sample preparation. To test whether the LSC sample pre-
paration procedure used previously and described here
was suitable for AMS measurement of
14C, a dose
response of Adriamycin–DNA adduct formation was
tested in Adriamycin sensitive and resistant MCF-7
breast cancer cells with 1–500nM Adriamycin treatments
for 4h. Importantly, no exogenous source of formalde-
hyde was used. Adriamycin–DNA adducts were clearly
detectable at doses as low as 10nM Adriamycin, with a
linear dose response from 10–500nM Adriamycin
(Figure 2A). However, when the results were extrapolated
to 2mM, the absolute Adriamycin–DNA adduct levels
were lower than expected, based on results obtained by
LSC (Table 2). By AMS measurement, 500nM
Adriamycin resulted in approximately 130 adducts/
10
7bp DNA (Figure 2A) whereas by LSC, 2mM
Adriamycin resulted in 1400±540 adducts/10
7bp DNA
as detected by LSC (Table 2). The lack of consistency is
likely to be due to the limited accuracy and reliability of
LSC detection at low levels of
14C. To address this varia-
tion, cells were treated with either 100nM or 1mM
Adriamycin and samples prepared for AMS measurement.
The 10-fold diﬀerence in Adriamycin concentration
resulted in a proportional increase in Adriamycin–DNA
adduct formation suggesting that the detection by AMS is
linear from 0 to 1mM (Table 2); however, adduct levels as
detected by AMS and LSC remained inconsistent. The
AMS and LSC sample preparation procedures diﬀer in
that AMS samples are dried onto ﬁlters, whereas solubi-
lized DNA is subjected to LSC. Extra measures are also
taken to prevent contamination in the ultra-sensitive AMS
procedure, although these factors are unlikely to result in
higher adduct levels as observed by LSC (Table 2). Using
AMS detection, the sensitivity of Adriamycin–DNA
adduct detection was increased by three orders of magni-
tude over LSC (Table 2 and Figure 2A).
MCF-7/Dx cells were also tested to investigate
the eﬀect of P-glycoprotein mediated resistance on
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Figure 2. Dose and time dependence of Adriamycin–DNA adduct for-
mation. (A) Dose response of adduct formation in [
14C]Adriamycin-
treated cells. MCF-7 cells were treated with 0, 25, 50, 75, 100, 200
and 500nM Adriamycin for 4h. MCF-7/Dx cells were treated with 0,
50, 100, 200 and 500nM Adriamycin for 4h. The zero Adriamycin
concentration samples represent vehicle-treated samples. Cellular
DNA was isolated and prepared for AMS analysis as described.
Values are expressed as Adriamycin–DNA adduct frequency per
10
7bp DNA and were obtained from between two and ﬁve independent
experiments (MCF-7) or one experiment with duplicate samples (MCF-
7/Dx). Error bars for 0–100nM points are SEM (n=3–5). Error bars
for 200 and 500nM points represent range (n=2). The full data set
(0–500nM Adriamycin) is shown in the inset. (B) Time course of
Adriamycin–DNA adduct formation. MCF-7 cells were treated with
100nM Adriamycin for 0, 0.5, 1, 2, 4 and 8h. Cellular DNA was
isolated and prepared for AMS analysis as described. Values are
expressed as mean Adriamycin–DNA adduct frequency per 10
7bp
DNA and were obtained from two replicate experiments. Error bars
represent range of two replicate experiments.
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Adriamycin-sensitive MCF-7 cells. The MCF-7/Dx cells
exhibited a similar linear trend in adduct levels between
0 and 500nM Adriamycin but overall lower adducts
were detected, consistent with reduced accumulation
of Adriamycin in the cells (Figure 2A). Overall, up to
3-fold lower Adriamycin–DNA adduct levels were detec-
ted in MCF-7/Dx cells compared to the Adriamycin-
sensitive MCF-7 cells.
Adriamycin–DNA adducts were measured throughout
the range of sensitivity achievable by AMS using the pro-
cedure described here. To assess the reproducibility of
AMS measurement of Adriamycin–DNA adducts at var-
ious levels of detection, two diﬀerent indicators of experi-
mental error were examined:
(1) intra-experimental error: the experimental error
within a single experiment (three experimental repli-
cates were utilized);
(2) inter-experimental error: the experimental error
between independent experiments (up to ﬁve inde-
pendent experiments).
The reproducibility of AMS measurements of
Adriamycin–DNA adducts is shown in Table 3. Intra-
experimental error (SD) for Adriamycin-treated samples
ranged from 7% to 13%, whereas inter-experimental error
ranged from 15% to 23% indicating that neither indepen-
dent experiments nor experimental replicates were subject
to high error. The error in drug-treated samples was not
elevated at low Adriamycin concentrations, indicating
that low levels of Adriamycin–DNA adducts did not
result in less reliable detection.
In order to assess the rate of formation of adducts
(in the absence of exogenous formaldehyde) MCF-7 cells
were treated with 100nM Adriamycin and adduct forma-
tion observed for up to 8h (Figure 2B). Adducts formed
rapidly, with the earliest observed adduct levels at 30min
after treatment and increased in a linear fashion over
0–8h, indicating that adduct formation was not limited
by exhaustion of Adriamycin or formaldehyde available
in the cellular environment, in this timeframe. Of the
dose of Adriamycin administered, only <0.1% was retai-
ned on DNA as Adriamycin adducts after the cleanup
procedure (8h post-treatment with 100nM Adriamycin),
indicating the enormous potential for enhancement of
Adriamycin–DNA adduct formation. It is expected
that under these conditions Adriamycin–DNA adduct
levels would be extensively enhanced by the supply of
formaldehyde-releasing pro-drugs, as demonstrated
previously (11,16,25).
The half-life of Adriamycin–DNA covalent lesions has
previously been measured by various techniques as 5–40h
(24,45). These studies used high Adriamycin concentra-
tions (up to 10mM) due to the limited sensitivity of the
techniques available, hence may not reﬂect the true half-
life of Adriamycin–DNA adducts formed at clinically-rele-
vant Adriamycin concentrations. A complex formalde-
hyde-generating system (DTT/iron) was also employed
for formation of Adriamycin–DNA adducts in these ear-
lier studies (38,46). The broad half-life observed was
thought to reﬂect a range of Adriamycin–DNA monoad-
ducts at isolated guanine residues, together with the pre-
ferred GpC dinucleotide binding site (most stable).
The decay of Adriamycin–DNA adducts at 378C was
measured by AMS for two purposes: to determine the
temporal stability of Adriamycin–DNA adducts formed
at clinically relevant Adriamycin concentrations and also
to compare the stability of Adriamycin–DNA adducts, as
previously described. Adriamycin–DNA adducts were
subjected to extended times at 378C and the results are
presented in Figure 3. The half-life for the decay of
Adriamycin–DNA adducts (in the ﬁrst three days) was
found to be  13h and this is expected to be of greater
relevance to the clinical situation than previous estimates
because of the lower doses employed and the fact that the
adducts were formed in tumour cells as opposed to a cell-
free system. The possibility that the observed loss of
adducts in the ﬁrst three days could be due to residual
intercalated drug (that had not been extracted by
phenol/chloroform treatments) is unlikely since interca-
lated Adriamycin has a half-life of less than 2s (47). Of
great potential signiﬁcance is the fact that  50% of the
population of adducts persisted for up to 12 days, with no
sign of decay after the initial decrease at early time points.
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Figure 3. Stability of Adriamycin–DNA adducts. DNA from MCF-7
cells treated with 100nM Adriamycin for 4h was prepared as for AMS
adduct measurement. DNA was then further subjected to incubation at
378C for the indicated times. Samples were then subjected to a second
phenol–chloroform extraction and prepared for AMS analysis as
described.
Table 2. Comparison of Adriamycin–DNA adducts detected by
LSC and AMS
Method of detection Adriamycin concentration Adducts/10
7bp DNA
AMS 100nM 37.6
AMS 1mM 442
LSC 2mM 1400±540
a
Cells were treated for 4h and Adriamycin–DNA adducts were
measured by AMS and LSC as described.
aError is SEM, n=5.
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were formed in tumour cells, their stability was assessed
in vitro following isolation of the DNA, and that under
cellular conditions the longevity of these adducts is likely
to be modiﬁed by DNA damage repair pathways.
In order to assess the cytotoxicity at such low levels
of drug, cells were treated with Adriamycin for 4h and
a small sub-sample of each treatment was assayed for
clonogenic survival. The remaining sample was assayed
for Adriamycin–DNA adducts by AMS. Since an identi-
cally drug-treated sample was sub-sampled to assay both
adducts and cell survival, the two results can be directly
compared to examine the involvement of Adriamycin–
DNA adducts in the cytotoxic response to Adriamycin.
The results are plotted together in Figure 4 to illustrate
the range of adduct levels that correspond to reduced cell
survival. A 50% loss of colony survival was detected at an
Adriamycin dose of 300nM, where approximately 21000
adducts were estimated to have formed per cell.
DISCUSSION
AMSas amethodology forthedetection
ofAdriamycin–DNA adducts
AMS measurement of radioisotopes exhibits higher sensi-
tivity than decay counting, is applicable to many tracer
radioisotopes (31) and has been cited as the most sensitive
method available for the detection of various DNA
adducts (32). AMS has exhibited over ﬁve orders of mag-
nitude higher sensitivity for detection of radiocarbon-
labelled Adriamycin compared to other routinely-used
assays such as HPLC (48). DNA adduct studies with
many DNA binders have also demonstrated linear dose
responses using AMS detection (31).
To develop an AMS procedure for Adriamycin–DNA
adduct measurement, adaptation of the LSC procedure
(16) involved modiﬁcations to maintain sample quality
and to the setting in which the procedure was carried
out. Minor changes were also made to the ﬁnal format
of the DNA samples to adapt to the requirements for
AMS detection (DNA samples are now routinely dried
onto ﬁlters for shipping to LLNL for AMS measurement).
Importantly, once the sample was dispensed onto the ﬁlter
paper, it was no longer necessary to maintain intact
Adriamycin–DNA adducts, and the ﬁlter could be
stored and shipped at room temperature. The use of sepa-
rate isolated reagents and equipment ensured sample con-
tamination was kept to a minimum with extensive controls
for routine monitoring of the process. The procedure
presented here routinely produced samples of suﬃcient
quality for AMS measurement.
The Adriamycin dose response (Figure 2A) demon-
strates speciﬁcity for Adriamycin–DNA adducts evi-
denced by the linear dose response (down to 10nM
Adriamycin) and the virtual absence of detectable
‘adducts’ in untreated controls (Table 3). The half-life of
 13h for the decay of adducts in the ﬁrst three days
is consistent with previous reports of the limited stability
of these adducts in vitro of 5–40h (10,11,23,24) and reﬂects
the known lability of aminal linkages. The persistent sub-
population of
14C lesions observed after 3 days (Figure 3)
could possibly be due to metabolic-activation of the
side chain of the C-12 of Adriamycin (leading to the
formation of an inter-strand cross-link at some adduct
sites), or to particularly stable lesions at speciﬁc DNA
sequences.
Using the procedure described here, AMS detection of
these adducts are of high reproducibility, both within
experimental replicates and between separate experiments
(Table 3). The day-to-day variation observed between
separate experiments is probably due to experimental
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Figure 4. Adduct levels and colony survival. MCF-7 cells were treated
with Adriamycin for 4h and adduct levels and colony survival
measured relative to an untreated control as described in Materials
and methods section.
Table 3. Reproducibility of AMS measurement of Adriamycin-DNA
adducts
Adriamycin
concentration (nM)
Level of
Adriamycin–DNA
adducts
Adducts/10
7bp
Mean±SD
a
(intra-expt)
Mean±SE
b
(inter-expt)
0 None 0.04±<0.012 0.04±<0.002
c
25 Low 5.32±0.48 4.24±0.96
d
100 Intermediate 22.8±3.0 19.0±2.8
e
500 High 109.2±7.6 131±22
f
MCF-7 cells were treated with 0, 25, 100 and 500nM Adriamycin for
4h. The zero Adriamycin concentration samples were vehicle-treated
samples. Cellular DNA was isolated and prepared for AMS analysis
as described. Values are expressed as Adriamycin–DNA adduct fre-
quency per 10
7bp of DNA.
aResults were obtained from three replicate samples prepared within
one experiment, values shown are average±SD; intra-expt, intra-
experimental.
bResults obtained from independent experiments, values presented are
average±SE (reproduced from Figure 2B: time course of Adriamycin–
DNA adduct formation. MCF-7 cells were treated with 100nM
Adriamycin for 0, 0.5, 1, 2, 4 and 8h. Cellular DNA was isolated
and prepared for AMS analysis as described. Values are expressed as
mean Adriamycin–DNA adduct frequency per 10
7bp DNA and were
obtained from two replicate experiments. Error bars represent range of
two replicate experiments) inter-expt, inter-experimental.
cn=3.
dn=3.
en=5.
fn=2, error is range.
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14C]Adriamycin stock to a
working concentration (typically a 10- to 100-fold dilu-
tion). The variation within experimental replicates is low
andisprobably due to the precision limits of the equipment
used, not sample contamination. The reproducibility of
AMS measurement of radioisotopes itself is very high (49).
AMS has successfully been used here to measure
Adriamycin–DNA adducts from cells in culture. There
is potential to develop this procedure for other applica-
tions such as studies of Adriamycin treatment in mice
and humans to establish the extent of formation of
Adriamycin–DNA adducts in tumour and normal tissues.
The same principle could also be applied to other DNA-
binding chemotherapeutic drugs as a biomarker of adducts
as a mechanism of action. For such applications the AMS
technique would need to be optimized to develop an appro-
priate experimental process such as the need for radiola-
belled compounds and suitable sample preparation.
Adriamycin–DNAadductformationasamechanismofaction
ofAdriamycin at clinically relevant drugconcentrations
There has been doubt whether adduct formation contri-
butes signiﬁcantly to the mechanism of action of
Adriamycin at clinically relevant concentrations of the
drug since adduct formation could not be proven at these
levels using the existing conventional assays [
32P post-
labelling, decay counting of radiolabelled Adriamycin
and the gene-speciﬁc cross-linking assay (summarized in
Table 1)]. The measurement of Adriamycin–DNA adducts
at clinical Adriamycin concentrations was critical to the
hypothesis that adducts contribute to the mechanism of
action of Adriamycin and to substantiate this hypothesis
the presence of Adriamycin–DNA adducts at low doses
needed to be demonstrated. The results presented here
indicate that adduct formation can readily be measured
at 10–500nM Adriamycin (Figure 2A), suggesting that
signiﬁcant levels of adducts form at clinically relevant
Adriamycin concentrations. These results demonstrate
adduct formation is a realistic mechanism of action
of Adriamycin that may operate during clinical use of
Adriamycin.
The commonly cited mechanism of action, topoisom-
erase inhibition, is likely to be a major player in the
overall cytotoxicity and therapeutic activity exerted
by Adriamycin; however, it should be noted that
Adriamycin is also likely to be a multimodal chemother-
apeutic that acts by many mechanisms in the clinical situa-
tion. The contribution of topoisomerase eﬀects in this
study are unknown; however, the lowest concentrations
of Adriamycin that have been reported to given rise to
detectable amounts of topoisomerase inhibition are in
the vicinity of 1mM (50–53). By comparison here,
Adriamycin–DNA adducts have been demonstrated at
concentrations as low as 10nM Adriamycin. Many lines
of evidence point to the possibility that topoisomerase IIa
inhibition is not the sole mechanism of action of
Adriamycin. Topoisomerase IIa activity in various cell
lines does not correlate with sensitivity to Adriamycin,
implying that cytotoxicity may be due to other factors
(54). Similarly, gene expression analysis has indicated
that topoisomerase IIa involvement in the mechanism of
action of supposed topoisomerase inhibitors is variable
and that Adriamycin and Adriamycin-like drugs do not
group with other topoisomerase inhibitors (55–58).
Adriamycin–DNA adducts are now also known to
induce apoptosis more rapidly and are more cytotoxic to
cells than topoisomerase-mediated eﬀects (44).
While uncertainty still exists regarding the mechanism
of action of Adriamycin, given this new evidence using
very low doses, Adriamycin–DNA adduct formation is a
mechanism of action of Adriamycin that must be consid-
ered. It is likely that many observations of the cellular
eﬀects induced by Adriamycin have been due (at least in
part) to Adriamycin–DNA adduct formation. This largely
unfamiliar mechanism of action of Adriamycin should be
more widely tested as a signiﬁcant contributor to this
important and widely used chemotherapeutic.
These ﬁndings are of particular signiﬁcance in light of
the widespread use of Adriamycin (and subsequent
Adriamycin-induced resistance) and the knowledge that
both Adriamycin treatment (59,60) and tumour burden
(61) correlate with increased formaldehyde levels in the
body. The ﬁnding that formaldehyde was involved in the
formation of Adriamycin–DNA adducts (12) was of par-
ticular interest because Adriamycin has long been known
to cause redox damage, a consequence of which is the
production of aldehydes (62). Formaldehyde generated
as a consequence of Adriamycin treatment has been
observed as a urinary metabolite in rats (59), mice (60)
and in MCF-7 cell lysates (46,63). The possibility exists
that formaldehyde is available in Adriamycin-treated
cells (whether it be from endogenous sources or as meta-
bolic products of Adriamycin itself) and if so, this would
facilitate the formation of Adriamycin–DNA adducts.
Intracellular formaldehyde was measured in various
cancer cell lines in culture and found to be 0–4mM
inside untreated cells (63). Tumour-bearing mice and
patients exhale more formaldehyde (61) and have higher
formaldehyde levels in tissue homogenates (64) than
non-tumour bearing controls. Bladder and prostate
cancer patients also have higher formaldehyde in their
urine than control samples from healthy subjects (65)
and a diagnostic test based on non-invasive measurements
of formaldehyde has been suggested as marker of prostate
and bladder cancer (65).
Although adduct formation accounts for only a small
percentage of total Adriamycin, it is a potent mechanism
of action that may be responsible for the reduced survival
capacity of the cells shown in Figure 4. Since these eﬀects
were observed in the absence of any exogenous formalde-
hyde source there is vast potential for enhancing the anti-
cancer activity of Adriamycin with formaldehyde sources
such as formaldehyde-releasing pro-drugs. This drug acti-
vation process has been extensively investigated and is the
subject of several recent reviews (10,11).
Highly sensitive detection of Adriamycin–DNA adducts
has long been thought the critical evidence required to
support the hypothesis that adducts are a likely mecha-
nism of action of Adriamycin (4). Here, a novel method
is presented for highly sensitive and speciﬁc detection of
adducts at clinically relevant Adriamycin concentrations
e100 Nucleic Acids Research, 2008, Vol. 36, No. 16 PAGE8 OF10using AMS methodology. Adriamycin–DNA adducts
form at doses and in a timeframe that correlate with
plasma concentrations of Adriamycin in patients.
Further support for this hypothesis could now be sought
using an in vivo model and AMS detection to demonstrate
whether Adriamycin–DNA adducts form in whole organ-
isms at clinically relevant drug doses.
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